EIC selects 43 Pathfinder projects to turn high‑risk research into prototypes
- ›The European Innovation Council has awarded grants of up to €4 million to 43 projects from the EIC Pathfinder Open 2026 call.
- ›Selected projects cover areas from cancer therapeutics and quantum computing to precision manufacturing and climate‑resilient agriculture.
- ›The 2026 Pathfinder Open was highly competitive and attracted a record number of proposals for a second consecutive year.
- ›Projects involve 218 organisations from 30 countries and will proceed to grant agreement preparation pending signature.
- ›Commercialisation, regulatory clearance and further financing remain major hurdles beyond Pathfinder funding.
EIC backs 43 high‑risk research projects to move toward prototypes
The European Innovation Council announced on 14 October 2026 that it selected 43 projects under the EIC Pathfinder Open 2026 call. Each award can provide up to €4 million in grant funding aimed at early stage, high‑risk research that could open new technological pathways. The winning projects span healthcare, quantum computing, advanced manufacturing and climate resilience among other fields. Winners have been notified and are preparing grant agreements. Funding is conditional on signing those agreements.
Scale and composition of the selection
The selected 43 projects bring together 218 organisations located in 30 countries including 24 EU member states. Across 266 consortium participations, participants are drawn largely from academia and research institutions. Reported breakdowns show 44 percent of participations came from higher or secondary education establishments, 28 percent from research organisations, 25 percent from private companies and 3 percent from other public bodies. Small and medium sized enterprises participate in 34 of the selected projects.
The 2026 Pathfinder Open received a record number of proposals for the second year running making it one of the most competitive instruments under Horizon Europe. Applicants collectively requested many times the available budget, underscoring demand for funding for ambitious, early stage research. The evaluation process for this call is now complete and successful applicants are moving into contracting.
Representative projects and what they aim to do
How the EIC Pathfinder fits into the innovation journey
The EIC Pathfinder funds early stage, high‑risk research at low technology readiness levels with the explicit aim of creating radically new technology directions. Grants typically support work at TRL 1 to 3 toward laboratory proof of concept and may fund translational activities up to prototype demonstration in later schemes. Beyond grant funding, beneficiaries can also engage with EIC Programme Managers and access tailored Business Acceleration Services intended to help projects identify pathways toward commercialisation or further investment.
Next steps for winners and remaining hurdles
All selected projects have been notified and will now prepare grant agreements. Disbursement of funds is conditional on signature of those agreements. For many Pathfinder projects, the real test begins after this milestone. Key challenges include scaling laboratory demonstrations into robust prototypes, securing additional capital to de‑risk commercial development, protecting and managing intellectual property, and navigating regulatory frameworks especially in areas such as therapeutics or bioengineered organisms.
The EIC expects to open its 2027 funding opportunities in early November, continuing its role in the Horizon Europe portfolio of instruments that aim to move bold research toward marketable innovation.
Context and implications for the European innovation ecosystem
The Pathfinder programme sits upstream in Europe’s innovation funnel, seeding high‑risk science that could spawn new markets or transformative industries. Selection of 43 projects across diverse disciplines demonstrates continued investor and researcher appetite for blue‑sky research. At the same time, the high demand and competitive success rates highlight persistent gaps in funding for later translational stages. Public grants at this level are valuable for proof of concept but do not by themselves guarantee deployment at scale. That gap is the rationale for linked instruments such as the EIC Transition, the Accelerator and the EIC Fund which aim to bridge to commercial financing and strategic capital.
Policymakers and programme managers should track not only the scientific outputs of these projects but also their ability to attract follow‑on funding, establish supply chains, and meet regulatory and ethical requirements. For projects in sensitive areas like engineered microbes or defence applications, oversight and robust risk management will remain essential.
Summary table of highlighted projects
| Project | Field | EIC grant (up to) | Primary ambition | Principal near‑term challenge |
| LUNGBOT | Oncology / synthetic biology | €4 million | Inhalable engineered bacteria to produce therapeutics directly in lung tumours | Biosafety, delivery, regulatory approval for modified organisms |
| NoBIQu | Quantum computing | €4 million | New superconducting qubit architecture with more efficient error correction | Hardware‑software integration, achieving fault tolerance with less overhead |
| DyHoLIT | Precision manufacturing / lithography | €4 million | Holographic lithography for ultra‑high resolution 3D structures | Optical stability, manufacturing throughput, semiconductor process integration |
| DEW2ROOT | Climate resilience / materials | €4 million | Wood‑based moisture harvester that transports water to plant roots | Material durability, scaling production, field validation under varied climates |
Risks and critical questions to watch
Biosecurity and ethics. Projects that deploy living engineered organisms require rigorous biosafety analyses, regulatory clarity and public engagement. Demonstrating benefit and managing risk are both necessary for societal acceptance.
Pathway to market. Pathfinder grants typically fund proof of concept. Project teams will need access to further translational funding, investor interest and technical partners to scale prototypes into products. Not all promising science can be commercialised at acceptable cost or speed.
Manufacturing and supply chains. Technologies claiming to transform manufacturing or materials must address production speed, reproducibility and interoperability with existing industrial processes. Without credible scale strategies, many high‑precision methods remain niche.
Regulation and standards. Breakthrough approaches often outrun existing standards. Engagement with regulators, early standardisation discussions and evidence generation are essential steps that projects must plan for from early stages.
Where to follow developments
The EIC publishes lists of selected projects and programme documents through EISMEA and the EIC work programme pages. Observers should track grant agreement signings, follow‑on funding rounds and participation in EIC portfolio activities which indicate whether projects are successfully moving toward commercialisation. For projects touching sensitive areas, monitoring independent biosafety and ethical reviews is important.